VERTEX PHARMACEUTICALVERTEX PHARMACEUTICALVERTEX PHARMACEUTICAL

VERTEX PHARMACEUTICAL

No trades
See on Supercharts

Price target

432.490.00 0.00%
The 27 analysts offering 1 year price forecasts for VX1 have a max estimate of — and a min estimate of —.

Analyst rating

Based on 34 analysts giving stock ratings to VX1 in the past 3 months.

EPS

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise

Revenue

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise
Be warned

Frequently Asked Questions

VX1 EPS for the last quarter is 4.41 EUR despite the estimation of 3.77 EUR. In the next quarter EPS is expected to reach 3.87 EUR. Track more of VERTEX PHARMACEUTICAL financials and stay on top of what is up with the company.
In the next quarter VERTEX PHARMACEUTICAL revenue is expected to reach ‪2.47 B‬ EUR. Check out VERTEX PHARMACEUTICAL revenue and earnings and make informed decisions.
According to analysts, VX1 price target is 432.49 EUR with a max estimate of 536.57 EUR and a min estimate of 302.23 EUR. Check if this forecast comes true in a year, meanwhile watch VERTEX PHARMACEUTICAL stock price chart and keep track of the current situation with VX1 news and stock market news.
We've gathered opinions of 34 analysts rating VX1 stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as buy. Note that it's not a trading advice — your own analysis is still required.